Supplying a Global Biotech Company in the US
Equivalent to 27.54% of Annual Revenue

ST Pharm has signed a supply contract worth KRW 91.3 billion for oligonucleotide active pharmaceutical ingredients (APIs) with a global biotech company in the United States. This marks the largest single oligonucleotide API supply contract to date.

Exterior view of ST Pharm headquarters in Siheung-si, Gyeonggi Province. ST Pharm

Exterior view of ST Pharm headquarters in Siheung-si, Gyeonggi Province. ST Pharm

View original image

On September 18, ST Pharm announced that it had entered into a supply contract with a US-based global biotech company, valued at $66,135,000 (approximately KRW 91.3 billion) for oligonucleotide APIs. The supply period extends from this year until November 2027. Due to confidentiality clauses, the client’s name has not been disclosed. The size of this contract represents 27.54% of ST Pharm’s annual revenue last year, which was KRW 331.7 billion.


Since the beginning of this year, ST Pharm has been continuously breaking its record for the largest single order value of oligonucleotide APIs. The company entered into a supply contract worth KRW 82.5 billion in January, followed by another contract worth KRW 89.7 billion in March. The latest contract surpasses both, expanding to KRW 91.3 billion.


ST Pharm is also expanding its production capacity in response to growth in the global oligonucleotide therapeutics market. Through the expansion of its second oligonucleotide building last year, the company has secured Asia’s largest and globally top-tier production capacity for oligonucleotide APIs.


The company is targeting demand from global pharmaceutical and biotech firms by providing integrated services, which not only include production and quality management but also support in process development, analysis, and regulatory approval beginning from the early development stages. ST Pharm also emphasizes its competitive edge based on its experience in complying with Good Manufacturing Practices (GMP) across the entire product lifecycle.


An official from ST Pharm stated, "We provide customer-tailored all-in-one services ranging from process development, analysis, and regulatory approval from the initial development stage," and added, "We will continue to expand collaboration with global big pharma and biotech companies based on our proven technology and expertise in the global market."



This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing